Did you know?
ChinaBio® Group is an investment, consulting and media firm helping western life science companies achieve success in China. ChinaBio works with U.S., European and APAC companies seeking partnerships, acquisitions, novel technologies and funding in China.  

>> Learn more…

Site Search

>> Advanced Search

  Quick Search:
 
 

Free Newsletter

  Email address:
   

Hisoar Pharma Raises $79 Million for Capital Projects

publication date: Feb 25, 2011
View a Printer Friendly version of this page, allowing you to print the page. Send a summary of this page to someone via email.
Zhejiang Hisoar Pharmaceutical will raise 520 million RMB ($79 million) in a private placement, issuing 25 million shares at 20.92 RMB ($3.18) each. Hisoar’s Chairman, Li Wei, will buy at least 10% of the offering. The great majority of the proceeds is earmarked for two major capital projects. Hisoar said the projects will add around 1.2 billion RMB ($182.5 million) in annual sales, once they are completed. More details....

Stock Symbol: (SHE: 002099)



Sorry... this feature or article is only available to subscribers.

>> Learn more about our subscription plans...

>> Free email newsletter...

>> Login...

Login

  

    
   
ChinaBio® Events
CBPF2016
Suzhou, China
May 18 - 19, 2016
Record attendance of 1008!
See us next year in Shunde!

>> More events...

Other Events
Hong Kong, China
June 15–17, 2016
Our Partners
Annual Sponsors
Official Partners
Supporting Partners
Media Sponsors